MedTrace Logo

HFNC and Acute Hypercapnic Respiratory Failure

NCT04109560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-10-23

No results posted yet for this study

Summary

High-flow nasal cannula (HFNC) enables delivering humidified gas at high-flow rates controlling the oxygen inspired fraction (FiO2). Its efficacy has been demonstrated in hypoxemic acute respiratory failure. However, little is known about its use in hypercapnic acute respiratory failure (ARF). Therefore, we aimed to evaluate the effect of using HFNC through "Precision Flow" equipment as first line of ventilatory support for COPD patients with hypercapnic acute respiratory failure.

Conditions

  • High Flow Oxygen Therapy
  • Acute Hypercapnic Respiratory Failure
  • COPD Exacerbation

Sponsors & Collaborators

  • Argentinian Intensive Care Society

    lead OTHER

Principal Investigators

  • Gustavo A Plotnikow · Sanatorio Anchorena Recoleta

  • Mariano Setten · Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC)

  • Norberto Tiribelli · Complejo Médico Policial Churruca-Visca

  • Sebastian Fredes · Sanatorio de la Trinidad Mitre

  • Matias Accoce · Sanatorio Anchorena San Martín

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109560 on ClinicalTrials.gov